AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00585195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: 600 mg QD administered from Cycle 1, Day 16 to Cycle 2, Day 1 (14 days of dosing) in combination with PF-02341066.
Study NCT00585195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Multiple Dose Design: 200 mg QD administered from Cycle 1, Day 1 to Cycle 1, Day 16 (16 days) in combination with PF-02341066.
Study NCT03327337 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Arthroscopic Assisted Balloon Tibioplasty
Description: Under arthroscopy, the balloon supports the articular surface, with additional bone graft and necessary internal fixation
Study NCT03327337 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arthroscopic Assisted Balloon Tibioplasty
Description: Under arthroscopy, the balloon supports the articular surface, with additional bone graft and necessary internal fixation
Study NCT02866539 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Polyherbal capsule coccinia, bougainvillea, catharanthus
Description: A unique combination of 3 herbs that lower blood sugars
Study NCT02866539 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Similar looking inactive powder
Study NCT01455857 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ITCA 650
Description: ITCA 650 is exenatide in DUROS
Study NCT01455857 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: ITCA placebo
Description: Formulation in DUROS (no exenatide)
Study NCT01937156 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SP-01 (Granisetron Transdermal Delivery System)
Description: SP-01 will be applied to the upper arm 24-48 hours before the start of chemotherapy, and left in place for 7 days.
Study NCT01937156 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Granisetron Hydrochloride Tablet
Description: Granisetron hydrochloride 1 mg tablets will be administered 1 hour before administration of chemotherapy at the first time, then taken 12 hours after the first dose later; 2 mg/day bid, for ≥ 2 days.
Study NCT04386187 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GSH Foods
Description: The intervention consists of customized foods/small meals that have been designed to be high in a single nutrient called glutathione (GSH).
Study NCT04386187 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutrition education about glutathione sources in the diet
Description: Four videos will outline food sources of glutathione, cooking methods to reduce systemic requirements for glutathione, food sources of nutrient cofactors for glutathione production and other related content.
Study NCT04386187 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care nutrition education for type 2 diabetes
Description: The educational control is provided with information on standard dietary interventions for diabetes as electronic handouts and web links.
Study NCT01162317 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Treatments will be performed by the PI, who is a licensed physician acupuncturist and has practiced acupuncture independently for 5 years with about 4000 patient/visit treatment history. A total of 10 acupuncture treatments represents a reasonable approach to optimal duration of treatment. Acupoint selection will be based on a combination of standardization and individualization for best treatment effects. At least 5 standardized body and auricular acupoints will be selected. Standardized sterile, disposable acupuncture needles will be applied for 20 minutes.
Study NCT01162317 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sham Acupuncture
Description: Treatments will be performed by the PI, who is a licensed physician acupuncturist and has practiced acupuncture independently for 5 years with about 4000 patient/visit treatment history. A total of 10 acupuncture treatments represent a reasonable approach to optimal duration of treatment. Acupoint selection will be based on a combination of standardization and individualization for best treatment effects. At least 5 standardized body and auricular acupoints will be selected. Standardized sterile, disposable acupuncture needles will be applied for 20 minutes. Each sham or real acupuncture needle will be applied through a tube as sham needles have blunt tip and telescopic shaft, the visual effect and percutaneous sensation of sham needle mimic the real needle penetration.
Study NCT00096343 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Study NCT00096343 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Study NCT01513577 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pedicle screws
Description: The control group received posterior fixation with pedicle screws through a midline approach. Through the approach bone was harvested from the right posterior iliac crest. Before closure of the posterior approach an epidural catheter and a drain was placed.
Study NCT01513577 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Percutaneous stab incisions
Description: The intervention group received posterior fixation through 6 percutaneous stab incisions with the use of the sextant system. Through a separate 3-4 cm long incision, bone was harvested from the right posterior iliac crest. After decorticating the transverse processes through the stab wounds, the bone graft was placed with a 10 ml cut syringe. An epidural catheter was placed at the end of the posterior procedure.
Study NCT03855423 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Tocotrienol-rich Fraction (TRF)
Description: TRF consists of alpha, gamma and delta tocotrienols in addition to small amount of alpha-tocopherol
Study NCT04098757 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Migratens
Description: 2 sachets/day: 800 mg of α-Lipoic acid, 450 mg of magnesium bisglycinate, 300 mg of L-Tryptophan, 20 mcg of Vitamin D3, 2.4 mg of Vitamin B2, 25 mg of Niacin, 150 mg of Coenzyme Q10. Patients who receive Migratens food supplementation have to take 2 sachets / day for 12 weeks. The supplement will be prescribed as usual and the assumption of the same will be recorded by partecipants in the appropriate daily; if the subject does not continue the indication the data collected up to that moment will be considered.
Study NCT03573349 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ketamine
Description: We will enroll 20 adults (aged 18-65 years) with treatment-resistant depression and will provide two i.v. ketamine infusions (0.5 mg/kg, infused over 40 minutes) and measure their depressive symptom responses. Biomarkers will be developed using blood samples from study subjects, taken prior to (predictive biomarkers), and following ketamine treatment (change biomarkers). This will be an open-label feasibility trial.
Study NCT00361660 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: functional task practice - distributed
Description: This functional task practice is modeled after Constraint-Induced Movement Therapy in which participants wear a mitt on the non-paretic arm for up to 90% of waking hours and then attend therapy for 3 hours a session Monday, Wednesday, and Friday in which they practice various functional tasks, such as tracing a stencil, placing toothbrushes in toothbrush holders, etc.
Study NCT00361660 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: functional task practice - condensed
Description: This functional task practice is modeled after Constraint-Induced Movement Therapy in which participants wear a mitt on the non-paretic arm for up to 90% of waking hours and then attend therapy for 3 hours a session Monday through Friday in which they practice various functional tasks, such as tracing a stencil, placing toothbrushes in toothbrush holders, etc.
Study NCT01201733 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional Thai massage
Description: The participants will receive a thirty minutes session of traditional Thai massage onto the scapular region
Study NCT01201733 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound therapy and hot pack
Study NCT02181387 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: administered every 6 hours by mouth up to 4 doses
Study NCT02181387 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00889018 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carboplatin
Description: Table. 1: Chemotherapy protocol Vincristine Etoposide Carboplatin Day1 + + + Day2 ---- + ---- This regimen is repeated once a month for 6 months.Dose:Vincristine: 1.5 mg/m2 (0.05 mg/kg for children £36 months old and maximum dose 2 mg).Etoposide: 150 mg/m2 (5 mg/kg for children £36 months old).Carboplatin: 560 mg/m2 (18.6 mg/kg for children £36 months old). .
Study NCT00889018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Table. 1: Chemotherapy protocol Vincristine Etoposide Carboplatin Day1 + + + Day2 ---- + ---- This regimen is repeated once a month for 6 months.Dose:Vincristine: 1.5 mg/m2 (0.05 mg/kg for children £36 months old and maximum dose 2 mg).Etoposide: 150 mg/m2 (5 mg/kg for children £36 months old).Carboplatin: 750 mg/m2 (25 mg/kg for children £36 months old).
Study NCT02314767 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Interpersonal Psychotherapy
Description: Patients were treated with IPT method, which was an active comparator vs treatment as usual
Study NCT02314767 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducational Group Therapy
Description: Patients were treated with PeGt method which was an active comparatos vs treatment as usual
Study NCT01822509 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV
Study NCT01822509 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01822509 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study NCT02823366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenofibrate
Study NCT02823366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UDCA
Study NCT02823366 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: UDCA
Study NCT00611312 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Training
Description: Intense cognitive training, two consecutive weeks, each weekday, 6 hours/day
Study NCT02677480 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Test group, probiotic tablets and gel
Description: Effect of probiotic tablets and gel on acidogenic bacteria
Study NCT02677480 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo group, placebo tablets and gel
Description: Effect of placebo tablets and gel on acidogenic bacteria
Study NCT01786187 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Light Physical Activity
Description: Conventional treatment for cancer as prescribed by the participant's health care providers and will receive a home-based light physical activity program to help manage a specific symptom related to cancer and cancer treatment.
Study NCT01786187 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Symptom Experience Report
Description: Conventional treatment for cancer as prescribed by the participant's health care providers and will receive planned, structured, weekly telephone visits to report the experience of symptoms and health-related quality of life information.
Study NCT01506453 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gabapentin
Description: Participants randomized to the active treatment arm will receive gabapentin 20mg/kg/day PO divided into 3 doses and rounded to the nearest 100 mg for capsules and 10 mg for liquid preparation.
Study NCT01506453 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Participants randomized to the placebo treatment arm will receive look-alike capsules or liquid in a respective capsule size or liquid measure equivalent to the active treatment arm, but which contain no active treatment.
Study NCT00950222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imipenem/Amikacin
Description: patients will received as empirical therapy for VAP imipenem associated with amikacin.
Study NCT04538443 — intervention group
Intervention type: OTHER
Intervention: functional capacity
Description: impact of hemodialysis on functional capacity in children with CKD
Study NCT04538443 — intervention group
Intervention type: OTHER
Intervention: muscle strength
Description: impact of hemodialysis on muscle strength in children with CKD
Study NCT04538443 — intervention group
Intervention type: OTHER
Intervention: Quality of life of children
Description: impact of hemodialysis on Quality of life in children with CKD
Study NCT04538443 — intervention group
Intervention type: OTHER
Intervention: Quality of life of families
Description: impact of hemodialysis on Quality of life of families of children with CKD
Study NCT04634929 — intervention group
Intervention type: PROCEDURE
Intervention: bariatric surgery
Description: bariatric surgery
Study NCT04634929 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: conservative diet
Description: conservative diet
Study NCT01328717 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Contour Link Investigational Blood Glucose Monitoring System
Description: Subjects with diabetes and study staff each performed Blood Glucose tests from the subject's capillary blood obtained from fingerstick using the Contour Link investigational meter.
Study NCT04323631 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Oral
Study NCT04323631 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: The control group will not receive hydroxychloroquine
Description: The control group will not receive hydroxychloroquine
Study NCT01548079 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ursodeoxycholic Acid (UDCA)
Description: 20mg/kg/day UDCA in three weeks
Study NCT01574391 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Epidrum
Description: Epidrum is used
Study NCT01944150 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous electrical nerve stimulation
Description: explanations about devices and their use are given to the patient during the first session. The right place where the electrodes should be placed on, the most effective programme (optimal electric frequency provided by the machine), intensity are tested by the nurse during 30 minutes lasting session
Study NCT01944150 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation and hypnosis
Description: explanations about devices and their use are given to the patient during the first session. The right place where the electrodes should be placed on, the most effective programme (optimal electric frequency provided by the machine), intensity are tested by the nurse. Following informations are collected by the second nurse: pain representation and its relief thoughts about a quiet place. TENS and hypnosis are associated in a unique 30 minutes session
Study NCT03407443 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exposure to Make the Connection messages
Description: Participants are exposed to Make the Connection messages (each approximately 3 minutes in length) weekly for over a four-month study period through the study mobile application.
Study NCT03407443 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active Control Group
Description: Participants are exposed to VA news clips/segments (each approximately 3 minutes in length) weekly for over a four-month study period through the study mobile application.
Study NCT01978522 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Randomisation of questionnaire receipt.
Description: 1. The self-completion questionnaire will be delivered to the participants via post a week after completing the CAPI.~2. Self-completion questionnaire handed to participants immediately after completing the CAPI.
Study NCT04049786 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoprolol 100 mg for CYP2D6 phenotyping
Description: Metoprolol is being used as probe drug to evaluate CYP2D6 activity. Single-dose of metoprolol 100 mg are being administrated orally.
Study NCT03059225 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: repetitive transcranial magnetic stimulation (rTMS)
Description: undergo contralesional 1Hz repetitive transcranial magnetic stimulation(rTMS) or high frequency ipsilesional rTMS for 10 daily sessions
Study NCT03059225 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham stimulation
Description: 2-week inhibitory non-dominate hemisphere rTMS program
Study NCT04719325 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Herbert screw
Description: Fracture line exposed through intra-oral approach. bone reduction into proper anatomical occlusion and application of Herbert screw
Study NCT04719325 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lag screw
Description: Fracture line exposed through intra-oral approach. bone reduction into proper anatomical occlusion. Application of either lag screw according to Champy's osteosynthesis lines.
Study NCT02035592 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Full dose blueberry
Description: Full dose: 26g of freeze dried blueberry powder to be incorporated into the habitual diet.~Dietary restrictions will be observed (i.e. avoidance of blueberry, and restricted intake of anthocyanin rich foods) for 21 days prior to the first assessment visit and throughout the study.
Study NCT02035592 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Half dose blueberry
Description: Half dose: 26g of freeze dried powder (containing 13g of freeze dried blueberry powder and 13g of placebo comparator material) to be incorporated into the habitual diet.~Dietary restrictions will be observed (i.e. avoidance of blueberry, and restricted intake of anthocyanin rich foods) for 21 days prior to the first assessment visit and throughout the study.
Study NCT02035592 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Control: 26g of placebo comparator material to be incorporated into the habitual diet.~Dietary restrictions will be observed (i.e. avoidance of blueberry, and restricted intake of anthocyanin rich foods) for 21 days prior to the first assessment visit and throughout the study.
Study NCT03532087 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab 120 mg
Description: Denosumab 120 mg every 3 weeks.
Study NCT03532087 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab 60 mg
Description: Denosumab 60 mg every 6 months.
Study NCT02770456 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High dose fish oil
Description: Four 0.72-gram gelatine capsules per day with fish oil providing 2.0 g/d lc-n3FA
Study NCT02770456 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low dose fish oil
Description: Four 0.72-gram gelatine capsules per day with a mixture of fish oil and olive oil providing 0.5 g/d lc-n3FA
Study NCT02770456 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Olive oil
Description: Four 0.72-gram gelatine capsules per day with olive oil providing 0 g/d lc-n3FA
Study NCT01341756 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Palliative Radiotherapy
Description: Palliative Radiotherapy to a total dose of 36Gy in 12 fractions
Study NCT03715582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trimetazidine
Description: Pills of masking drug - trimetazidine
Study NCT03715582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Oral Tablet
Description: Pills of masking drug - placebo
Study NCT02784054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Study NCT02784054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Study NCT02784054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Study NCT02784054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bleomycin
Study NCT02784054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa
Study NCT02784054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Study NCT02784054 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Reduced dose radiotherapy
Study NCT02844725 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VVZ-149 injections
Description: Colorless, transparent liquid in water for injection
Study NCT02844725 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: water for injection
Study NCT00433459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: drug is used in first line treatment in combination (COPP or COPDAC)
Study NCT00433459 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide
Description: drug is used in first line treatment in combination (COPP or COPDAC)
Study NCT00433459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dacarbazine
Description: drug is used in first line treatment in combination (COPDAC)
Study NCT00433459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisolone
Description: drug is used in first line treatment in combination (OEPA, COPP or COPDAC)